

HR 6043

Fair Accountability and Innovative Research Drug Pricing Act of 2016

Congress: 114 (2015–2017, Ended)

Chamber: House

Policy Area: Health

Introduced: Sep 15, 2016

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Sep 15, 2016)

Official Text: <https://www.congress.gov/bill/114th-congress/house-bill/6043>

Sponsor

Name: Rep. Schakowsky, Janice D. [D-IL-9]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors (18 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cummings, Elijah E. [D-MD-7]	D · MD		Sep 15, 2016
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		Sep 15, 2016
Rep. Doggett, Lloyd [D-TX-35]	D · TX		Sep 15, 2016
Rep. Kirkpatrick, Ann [D-AZ-1]	D · AZ		Sep 15, 2016
Rep. McDermott, Jim [D-WA-7]	D · WA		Sep 15, 2016
Rep. Welch, Peter [D-VT-At Large]	D · VT		Sep 15, 2016
Rep. Blumenauer, Earl [D-OR-3]	D · OR		Sep 20, 2016
Rep. Castor, Kathy [D-FL-14]	D · FL		Sep 20, 2016
Rep. Conyers, John, Jr. [D-MI-13]	D · MI		Sep 20, 2016
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Sep 20, 2016
Rep. Nadler, Jerrold [D-NY-10]	D · NY		Sep 20, 2016
Rep. Pocan, Mark [D-WI-2]	D · WI		Sep 20, 2016
Rep. Yarmuth, John A. [D-KY-3]	D · KY		Sep 20, 2016
Rep. Lynch, Stephen F. [D-MA-8]	D · MA		Sep 26, 2016
Rep. Moore, Gwen [D-WI-4]	D · WI		Sep 26, 2016
Rep. Walz, Timothy J. [D-MN-1]	D · MN		Sep 26, 2016
Rep. Lujan Grisham, Michelle [D-NM-1]	D · NM		Nov 14, 2016
Rep. Pingree, Chellie [D-ME-1]	D · ME		Nov 14, 2016

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Sep 15, 2016

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
114 S 3335	Identical bill	Sep 15, 2016: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Sep 15, 2016)

Fair Accountability and Innovative Research Drug Pricing Act of 2016

This bill amends the Public Health Service Act to require manufacturers of certain drugs and biological products to report to the Department of Health and Human Services (HHS) price increases that result in a 10% or more increase in the price of a drug over a 12-month period. Reports are required for prescription drugs and drugs commonly administered in hospitals, except vaccines, drugs for rare conditions, and drugs with annual sales for Medicare and Medicaid enrollees of less than \$1.

Manufacturers that do not submit a required report are subject to a civil penalty. The Inspector General of HHS must review drug price information to determine compliance. Collected penalty funds must be used to carry out activities related to this reporting requirement and to improve consumer and provider information about drug value and drug price transparency.

HHS must publish manufacturer reports, a summary of those reports, and supporting analyses.

Actions Timeline

- **Sep 15, 2016:** Introduced in House
- **Sep 15, 2016:** Referred to the House Committee on Energy and Commerce.